TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Efficacy of Low and High Carbohydrate Diets
Brief Summary: This study will compare the safety and effectiveness of a low carbohydrate diet (Atkins Diet) with a high carbohydrate diet (conventional USDA diet).


Options:
A: Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
C: Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie
D: Arm Label: Full fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Full fat dairy | Arm Label: Low fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Low fat dairy | Arm Label: Control group; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Full fat dairy; Assigned to Arm(s): Full fat dairy group | Intervention Type: OTHER; Name: Low fat dairy; Assigned to Arm(s): Low fat dairy group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Efficacy of Low and High Carbohydrate Diets
Brief Summary: This study will compare the safety and effectiveness of a low carbohydrate diet (Atkins Diet) with a high carbohydrate diet (conventional USDA diet).


Options:
A: Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie
B: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
C: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Efficacy of Low and High Carbohydrate Diets
Brief Summary: This study will compare the safety and effectiveness of a low carbohydrate diet (Atkins Diet) with a high carbohydrate diet (conventional USDA diet).


Options:
A: N/A
B: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ADA 2003 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic index (LGI) diet | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MUFA diet | Intervention Type: BEHAVIORAL; Name: MUFA diet; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: ADA 2003; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Glycemic index (LGI) diet; Assigned to Arm(s): 2
D: Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renin Angiotensin System Blockage-DN (RASS)
Brief Summary: To determine if renin angiotensin medications can prevent or delay the onset of diabetic kidney disease.


Options:
A: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renin Angiotensin System Blockage-DN (RASS)
Brief Summary: To determine if renin angiotensin medications can prevent or delay the onset of diabetic kidney disease.


Options:
A: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Medication Management with Home BP Telemonitoring | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Combined intervention with Home BP Telemonitoring | Intervention Type: BEHAVIORAL; Name: Nurse Behavioral intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Nurse Medication Management with Home BP Telemonitoring; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: Nurse Combined intervention with Home BP Telemonitoring; Assigned to Arm(s): Arm 4
B: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: optimised treatment | Intervention Type: PROCEDURE; Name: optimised treatment; Assigned to Arm(s): Intervention
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renin Angiotensin System Blockage-DN (RASS)
Brief Summary: To determine if renin angiotensin medications can prevent or delay the onset of diabetic kidney disease.


Options:
A: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Double-blind, Randomised, Parallel-group, Multi-centre Study Evaluating the Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD, According to Swedish Guidelines (SPIRIMILD)
Brief Summary: To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines.


Options:
A: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
D: Arm Label: F 4.5 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 4.5mg | Arm Label: F 9.0 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 9 mg | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Turbuhaler® placebo | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 4.5mg; Assigned to Arm(s): F 4.5 bid | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 9 mg; Assigned to Arm(s): F 9.0 bid | Intervention Type: DRUG; Name: Turbuhaler® placebo; Assigned to Arm(s): PBO

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Double-blind, Randomised, Parallel-group, Multi-centre Study Evaluating the Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD, According to Swedish Guidelines (SPIRIMILD)
Brief Summary: To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines.


Options:
A: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
B: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Arm Label: tiotropium 18mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 18 mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: azithromycin (drug); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Triple therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol and tiotropium | Arm Label: Combination therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Budesonide/formoterol and placebo | Intervention Type: DRUG; Name: Budesonide/formoterol and tiotropium; Assigned to Arm(s): Triple therapy | Intervention Type: DRUG; Name: Budesonide/formoterol and placebo; Assigned to Arm(s): Combination therapy
D: Arm Label: ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Arm Label: SPIRIVA® HANDIHALER® inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium Bromide | Intervention Type: DRUG; Name: Tiotropium Bromide; Assigned to Arm(s): SPIRIVA® HANDIHALER® inhaler | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: NHW COPD Participants; Type: N/A; Interventions: N/A | Arm Label: NHW Control Group; Type: N/A; Interventions: N/A | Arm Label: AA COPD Participants; Type: N/A; Interventions: N/A | Arm Label: AA Control Group; Type: N/A; Interventions: N/A
C: Arm Label: Smokers without COPD; Type: N/A; Interventions: N/A | Arm Label: Severe COPD; Type: N/A; Interventions: N/A | Arm Label: Mild/Moderate COPD; Type: N/A; Interventions: N/A | Arm Label: Non-smokers; Type: N/A; Interventions: N/A
D: Arm Label: NPPV group; Type: EXPERIMENTAL; Interventions: Device: ventilators designed for non invasive ventilation | Arm Label: control gorup; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ventilators designed for non invasive ventilation; Assigned to Arm(s): NPPV group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
C: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg, Drug: Placebo to salmeterol | Arm Label: Salmeterol 50 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 µg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Salmeterol 50 µg; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Salmeterol 50 µg | Intervention Type: DRUG; Name: Placebo to salmeterol; Assigned to Arm(s): Indacaterol 150 µg
D: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium (Spiriva®); Assigned to Arm(s): N/A

Answer: A